Qing Kay Li
Johns Hopkins Medical Institutions, USA
Title: Immunobiomarkers for immunotherapy in non-small cell lung carcinoma
Biography
Biography: Qing Kay Li
Abstract
Specific immunotherapies have been developed, and they are approved by the FDA for clinical anti-cancer therapy. These agents are mainly monoclonal antibodies. Prior to applying these immunotherapy agents, one must determine the level of expression of target biomarkers on tumor cells by using specific IHC stains. Lack of knowledge of immunotherapy could have a negative impact on patient care. We will discuss: (1) update on how immunotherapy has rapidly integrated into standard care in oncology, (2) issues in the immunotherapy paradigm, including evolving standards of care in the multidisciplinary management of cancer patients, (3) selection criteria of tumor sample for IHC testing, particularly the adequacy criteria for PD-L1/PD-1 IHC testing.